Skip to main content

Table 1 Baseline characteristics of 150 participants with nontuberculous mycobacterial lung disease at study entry

From: Characteristics associated with progression in patients with of nontuberculous mycobacterial lung disease : a prospective cohort study

 

Total patients (N = 150)

Progressed (N = 47)

Not progressed (N = 103)

p-value

Age, years

64 [55–72]

62 [54–68]

66 [56–74]

0.030

Sex, female

92 (61.3)

32 (68.1)

60 (58.3)

0.251

Smoking

   

0.160

 Ever-smoker

40 (26.6)

9 (19.2)

31 (30.1)

 

 Never-smoker

110 (73.3)

38 (80.9)

72 (69.9)

 

Past medical history

    

 Tuberculosis

55 (36.9)

20 (43.5)

35 (34.0)

0.267

 Measles

29 (19.3)

7 (14.9)

22 (21.4)

0.352

 Pertussis

7 (4.7)

3 (6.4)

4 (3.9)

0.678

Comorbidity

    

 COPD

27 (18.8)

6 (12.8)

21 (21.6)

0.200

 Asthma

4 (2.8)

0 (0)

4 (4.1)

0.304

 Diabetes

14 (9.3)

5 (10.6)

9 (8.7)

0.765

 Malignancy

20 (13.3)

4 (8.5)

16 (15.5)

0.241

Symptom at initial visit

 Cough

61 (40.7)

23 (48.9)

38 (36.9)

0.164

 Sputum

108 (72.0)

35 (74.5)

73 (70.9)

0.649

 Dyspneaa

15 (10.0)

3 (6.4)

12 (11.3)

0.392

 Hemoptysis

29 (19.3)

13 (27.7)

16 (15.5)

0.081

 Fever

19 (12.7)

5 (10.6)

14 (13.6)

0.614

 Weight loss

17 (11.3)

8 (17.0)

9 (8.7)

0.138

Abnormal breath sounds

20 (13.3)

9 (19.1)

11 (10.7)

0.157

 Crackles

11 (7.3)

4 (8.5)

7 (6.8)

0.741

 Wheezing

13 (8.7)

7 (14.9)

6 (5.8)

0.113

Anxietyb

29 (19.3)

11 (23.4)

18 (17.5)

0.394

Depressionb

41 (27.3)

16 (34.0)

25 (24.3)

0.213

SGRQ

21.2 [11.3–35.2]

24.4 [12.7–44.1]

19.8 [10.3–30.6]

0.011

Radiologic features

   

0.599

 Nodular bronchiectatic disease

135 (90)

41 (30.4)

94 (69.6)

 

 Fibrocavitatary disease

14 (9.3)

6 (42.9)

8 (57.1)

 

 Unclassifiable

1 (0.7)

0 (0)

1 (1.0)

 

Chest CT scorec

10 [7–13]

13 [8–15]

9 [7–12]

<0.001

Radiologic deteriorationd

58/130 (44.6)

21/27 (77.8)

37/103 (35.9)

<0.001

Presence of cavity

37 (24.7)

24 (51.1)

13 (12.6)

<0.001

Pulmonary function

 FVC, L

2.83 [2.32–3.42]

2.54 [2.23–3.16]

2.97 [2.36–3.48]

0.032

 FVC, %

93 [81–101]

88 [79–95]

94 [82–106]

0.005

 FEV1, L

2.09 [1.76–2.48]

2.11 [1.77–2.38]

2.08 [1.73–2.51]

0.532

 FEV1, %

97 [82–110]

93 [82–105]

99 [81–113]

0.205

 DLCO, %

93 [80–106]

93 [80–104]

93 [81–107]

0.998

Cholesterol, mg/dL

182 [161–204]

178 [146–202]

183 [167–205]

0.229

Albumin, g/dL

4.3 [4.0–4.4]

4.2 [4.0–4.4]

4.3 [4.1–4.5]

0.031

  1. Data are presented as median [interquartile range] or proportion (%)
  2. COPD, chronic obstructive pulmonary disease; SGRQ, St. George’s Respiratory Questionnaire; CT, computed tomography; FVC, forced vital capacity; FEV 1 , forced expiratory volume in 1 s; DLCO, diffusing capacity for carbon monoxide
  3. aDyspnea was defined as modified Medical Research Council score ≥ 2
  4. bHospital Anxiety and Depression Scale (HADS), same or > 8
  5. cScores were given by considering the severity of bronchiectasis (maximum score, 9), cellular bronchiolitis (maximum score, 6), cavity (maximum score, 9), nodules (maximum score, 3) and consolidation (maximum score, 3). Maximum score possible was 30
  6. dRadiologic deterioration was defined as a one-point increment in the CT score on follow-up CT scans of the chest. Follow-up CT scans taken before the initiation of treatment were available in 27 out of 47 patients in whom nontuberculous mycobacterial lung disease progressed
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us